表紙
市場調查報告書

肝素酶:開發平台分析

Heparanase - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 359839
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
肝素酶:開發平台分析 Heparanase - Pipeline Review, H1 2020
出版日期: 2020年03月31日內容資訊: 英文 43 Pages
簡介

本報告提供以肝素酶為標的的藥物之適應症,開發階段,作用機制,給藥途徑及各分子類型分析,提供您藥物的藥理作用相關記述,迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

肝素酶概要

治療藥的開發

肝素酶:開發中的產品 - 各開發階段

肝素酶:開發中的產品 - 各治療範圍

肝素酶:開發中的產品 - 各適應症

肝素酶:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

肝素酶:企業開發中的產品

肝素酶:大學/機關開發中的產品

肝素酶:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

肝素酶的治療藥開發企業

  • Momenta Pharmaceuticals, Inc.
  • Progen Pharmaceuticals Limited
  • Sigma-Tau S.p.A.

藥物簡介

肝素酶:暫停中的計劃

肝素酶:開發中止的產品

肝素酶:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2336TDB

Summary:

According to the recently published report 'Heparanase - Pipeline Review, H1 2020'; Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Heparanase is an endoglycosidase which cleaves heparan sulfate (HS) and hence participates in degradation and remodeling of the extracellular matrix (ECM). Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation. Among these, are the enhancement of Akt signaling, stimulation of PI3K- and p38-dependent endothelial cell migration, and up regulation of VEGF, all contributing to its potent pro-angiogenic activity. Inhibiting the enzyme is beneficial in treatment of cancer.

The report 'Heparanase - Pipeline Review, H1 2020' outlays comprehensive information on the Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology and Immunology which include indications Retinopathy, Breast Cancer, Dry (Atrophic) Macular Degeneration, Head And Neck Cancer, Inflammation, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Refractory Multiple Myeloma, Solid Tumor and Wet (Neovascular / Exudative) Macular Degeneration.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)
  • The report reviews Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Overview
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Companies Involved in Therapeutics Development
  • Beta Therapeutics Pty Ltd
  • CarboMimetics
  • HepaRx Ltd
  • Leadiant Biosciences Inc
  • Zucero Therapeutics Ltd
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Drug Profiles
  • Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Bone Marrow Transplant Rejection and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BT-2180 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CM-30119 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pixatimod - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Dormant Products
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Discontinued Products
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 21, 2014: European Patent Office Intention to Grant 'Sulfated Oligosaccharide Derivatives' Patent
  • Oct 29, 2013: PG545 Phase 1 Cancer Trial Update
  • Jul 09, 2013: PG545 Pre-Clinical Data in Experimental Pancreatic Cancer Models Published in Molecular Cancer Therapeutics
  • May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001
  • May 30, 2012: Progen Pharma Obtains Australian Patent For Heparan Sulfate Mimetic Compounds
  • Sep 20, 2011: Progen Announces Closure Of PG545 Phase Ia Clinical Trial
  • Oct 14, 2009: New Preclinical Data Confirms PG545 As A Promising Clinical Candidate For Cancer
  • Apr 14, 2008: Progen Pharmaceuticals Announces presenttion Of New Data On PG500 Series Of Compounds At The AACR Meeting In San Diego
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Beta Therapeutics Pty Ltd, H1 2020
  • Pipeline by CarboMimetics, H1 2020
  • Pipeline by HepaRx Ltd, H1 2020
  • Pipeline by Leadiant Biosciences Inc, H1 2020
  • Pipeline by Zucero Therapeutics Ltd, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020